Results 1 to 10 of about 703 (68)

Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up

SAGE Open Medicine, 2014
Objective: To determine the safety and efficacy of long-term use of mizoribine by undertaking a 3-year post-marketing surveillance study. Methods: Subjects were all lupus nephritis patients newly treated with mizoribine between 1 October 2003 and 30 ...
Nobuyuki Yagi, Kenya Okada, Yohei Sudo, Hiromichi Itoh, Hisao Yoshida, Tatsuhiko Kuroda   +5 more
doaj   +2 more sources

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)

Journal of Diabetes Investigation, 2021
Aims/Introduction Tofogliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor that lowers plasma glucose levels by enhancing urinary glucose excretion.
Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Kohei Kaku   +7 more
doaj   +1 more source

Correction to: Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study

BMC Ophthalmology, 2020
An amendment to this paper has been published and can be accessed via the original article.
Hidenobu Tanihara, Takahiko Kakuda, Tetsuro Sano, Takashi Kanno, Ryoji Gunji   +4 more
doaj   +1 more source

Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study

BMC Ophthalmology, 2020
Background Ripasudil is approved in Japan for glaucoma or ocular hypertension (OH) when other treatments are ineffective or cannot be administered. Its long-term safety and efficacy are being examined in a post-marketing surveillance study; 12-month data
Hidenobu Tanihara, Takahiko Kakuda, Tetsuro Sano, Takashi Kanno, Ryoji Gunji   +4 more
doaj   +1 more source

Postmarketing observational study on the safety of 2021/2022 and 2022/2023 influenza vaccination campaigns in Italy: TheShinISS-Vax|Flu study protocol

BMJ Open, 2023
Introduction The purpose of TheShinISS-Vax|Flu study is to examine the association between influenza vaccines and adverse events requiring hospital admission or emergency care during the influenza vaccination campaigns 2021/2022 and 2022/2023 in Italy ...
Roberto Da Cas, Marco Massari, Stefania Spila Alegiani, Francesca Menniti-Ippolito, Cristina Morciano, Patrizia Felicetti, Pasquale Marchione, Fiorella Petronzelli, Anna Rosa Marra   +8 more
doaj   +1 more source

Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines

Pharmaceuticals, 2022
Considering the clinical significance for myocarditis and pericarditis after immunization with mRNA COVID-19 vaccines, the present pharmacovigilance study aimed to describe these events reported with mRNA COVID-19 vaccines in the Vaccine Adverse Events ...
Concetta Rafaniello, Mario Gaio, Alessia Zinzi, Maria Giuseppa Sullo, Valerio Liguori, Marialuisa Ferraro, Fiorella Petronzelli, Patrizia Felicetti, Pasquale Marchione, Anna Rosa Marra, Francesco Rossi, Antonella De Angelis, Annalisa Capuano   +12 more
doaj   +1 more source

Single‐pill combination of cilnidipine, an l‐/n‐type calcium channel blocker, and valsartan reduces the day‐by‐day variability of morning home systolic blood pressure in patients with treated hypertension: A sub‐analysis of the HOPE‐combi survey

The Journal of Clinical Hypertension, 2021
We examined the effects of a fixed‐dose single‐pill combination of cilnidipine (10 mg), an L‐/N‐type calcium channel blocker, and valsartan (80 mg) (SPC of Cil/Val) on the day‐by‐day variability of morning home systolic blood pressure (MHSBP) in 616 ...
Kazuomi Kario, Saori Matsuda, Shinobu Nagahama, Yoshiki Kurose, Hitoshi Sugii, Tsukasa Teshima, Noriyuki Suzuki   +6 more
doaj   +1 more source

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT)

Journal of Diabetes Investigation, 2020
Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3‐year study of tofogliflozin in patients with type 2 diabetes
Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Ryusuke Koshida, Hiroyuki Kameda, Masahiro Tamura, Kohei Kaku   +9 more
doaj   +1 more source

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world practice: Results of 12‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)

Journal of Diabetes Investigation, 2020
Aims/Introduction Due to the paucity of tofogliflozin data, we assessed the safety and effectiveness of tofogliflozin among Japanese patients with type 2 diabetes mellitus in the clinical setting, stratifying the patients by age, sex, estimated ...
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Kohei Kaku   +8 more
doaj   +1 more source

Repeat confirmatory testing for persons with discordant whole blood and oral fluid rapid HIV test results: findings from post marketing surveillance. [PDF]

PLoS ONE, 2008
BACKGROUND: Reactive oral fluid and whole blood rapid HIV tests must be followed with a confirmatory test (Western blot (WB), immunofluorescent assay (IFA) or approved nucleic acid amplification test (NAAT)).
Laura G Wesolowski, Duncan A Mackellar, Steven F Ethridge, Julia H Zhu, S Michele Owen, Patrick S Sullivan, Post Marketing Surveillance Team   +6 more
doaj   +1 more source